This is a grant renewal for studies on formulations of high molecular weight (MW>100 Daltons) pharmaceutical agents, such as DNA. Specifically, we plan to apply our understanding and experience in protein stabilization and controlled release system to the stabilization and controlled release of plasmid DNA. The significance of controlled release DNA lies in the significance of gene therapy. Currently, there are almost 400 gene therapy protocols. In clinical trials worldwide spanning a range of disease states (e.g., cancer, monogenic diseases, infectious diseases). The safe and effective delivery of gene therapeutics remains elusive and is currently a bottleneck for gene delivery. The stabilization of DNA in viable long-term pharmaceutical preparations is one critical part toward the advance of gene therapy to the clinic. There is a clear lack of understanding of the physical and chemical degradation of plasmid DNA in pharmaceutical systems, particularly with respect to degradation within hydrophobic polymer matrices. It is necessary to understand the relationship among plasmid DNA degradation pathways that occur under these conditions to begin designing rational methods for their stabilization. Therefore, our Specific Aims are: 1) Identify the principal non-enzymatic degradation pathways of supercoiled, nicked and linear plasmid DNA as a function of dehydration method, DNA packing, DNA hydration, and DNA conformation, (2) Identify new DNA stabilizing excipients or excipient combinations, 3) identify the principal non- enzymatic degradation pathways of supercoiled, nicked and linear plasmid DNA degradation in fully hydrated polymer-based controlled release systems,, the DNA-containing systems will be placed under a wide range of pharmaceutically relevant conditions and the degradation patterns identified by established analytical tools. The long-term objectives of this research are to develop robust DNA stabilization methods to meet the pharmaceutical requirements for controlled release gene delivery systems.

Agency
National Institute of Health (NIH)
Institute
National Institute of General Medical Sciences (NIGMS)
Type
Research Project (R01)
Project #
2R01GM026698-21
Application #
6193686
Study Section
Surgery and Bioengineering Study Section (SB)
Program Officer
Okita, Richard T
Project Start
1979-07-01
Project End
2004-08-31
Budget Start
2000-09-01
Budget End
2001-08-31
Support Year
21
Fiscal Year
2000
Total Cost
$287,760
Indirect Cost
Name
Massachusetts Institute of Technology
Department
Engineering (All Types)
Type
Schools of Engineering
DUNS #
City
Cambridge
State
MA
Country
United States
Zip Code
02139
Schroeder, Avi; Goldberg, Michael S; Kastrup, Christian et al. (2012) Remotely activated protein-producing nanoparticles. Nano Lett 12:2685-9
Devitt, Gerard; Thomas, Mini; Klibanov, Alexander M et al. (2007) Optimized protocol for the large scale production of HIV pseudovirions by transient transfection of HEK293T cells with linear fully deacylated polyethylenimine. J Virol Methods 146:298-304
Thomas, Mini; Lu, James J; Zhang, Chengcheng et al. (2007) Identification of novel superior polycationic vectors for gene delivery by high-throughput synthesis and screening of a combinatorial library. Pharm Res 24:1564-71
Sharma, Vikas K; Klibanov, Alexander M (2007) Moisture-induced aggregation of lyophilized DNA and its prevention. Pharm Res 24:168-75
Berry, David; Lynn, David M; Berry, Eric et al. (2006) Heparin localization and fine structure regulate Burkitt's lymphoma growth. Biochem Biophys Res Commun 348:850-6
Thomas, Mini; Ge, Qing; Lu, James J et al. (2005) Cross-linked small polyethylenimines: while still nontoxic, deliver DNA efficiently to mammalian cells in vitro and in vivo. Pharm Res 22:373-80
Sharma, Vikas K; Thomas, Mini; Klibanov, Alexander M (2005) Mechanistic studies on aggregation of polyethylenimine-DNA complexes and its prevention. Biotechnol Bioeng 90:614-20
Colombo, Gaia; Padera, Robert; Langer, Robert et al. (2005) Prolonged duration local anesthesia with lipid-protein-sugar particles containing bupivacaine and dexamethasone. J Biomed Mater Res A 75:458-64
Haining, W Nicholas; Anderson, Daniel G; Little, Steven R et al. (2004) pH-triggered microparticles for peptide vaccination. J Immunol 173:2578-85
Klibanov, Alexander M; Schefiliti, Jennifer A (2004) On the relationship between conformation and stability in solid pharmaceutical protein formulations. Biotechnol Lett 26:1103-6

Showing the most recent 10 out of 90 publications